Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
January 5, 2022 Presentation

Aptose Corporate Presentation January 2022

Aptose Corporate Presentation January 2022: View Presentation
December 13, 2021 Presentation

Aptose Corporate Update at ASH 2021

Aptose Corporate Update at ASH 2021: View Presentation
December 13, 2021 Poster

2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS

2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS: View Poster
December 13, 2021 Presentation

2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML

2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML: View Presentation
December 11, 2021 Poster

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML: View Poster
December 11, 2021 Poster

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies: View Poster
June 11, 2021 Presentation

Aptose Corporate Update at EHA 2021

Aptose Corporate Update at EHA 2021: View Presentation
June 11, 2021 Poster

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies: View Poster
June 11, 2021 Poster

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS: View Poster